WallStreetZenWallStreetZen

NASDAQ: BEAM
Beam Therapeutics Inc Stock

$22.93+1.02 (+4.66%)
Updated Nov 1, 2024
BEAM Price
$22.93
Fair Value Price
N/A
Market Cap
$1.89B
52 Week Low
$18.85
52 Week High
$49.50
P/E
-14.07x
P/B
2.21x
P/S
5.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$352.57M
Earnings
-$143.01M
Gross Margin
100%
Operating Margin
-40.16%
Profit Margin
-40.6%
Debt to Equity
0.48
Operating Cash Flow
-$137M
Beta
1.49
Next Earnings
Nov 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BEAM Overview

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BEAM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BEAM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BEAM is good value based on its book value relative to its share price (2.21x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
BEAM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BEAM due diligence checks available for Premium users.

Be the first to know about important BEAM news, forecast changes, insider trades & much more!

BEAM News

Valuation

BEAM price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-14.07x
Industry
-103.77x
Market
22.23x

BEAM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.21x
Industry
5.8x
BEAM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BEAM's financial health

Profit margin

Revenue
$11.8M
Net Income
-$91.1M
Profit Margin
-773.5%
BEAM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BEAM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.3B
Liabilities
$407.2M
Debt to equity
0.48
BEAM's short-term assets ($1.03B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BEAM's short-term assets ($1.03B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BEAM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$83.0M
Investing
$87.5M
Financing
$133.0k
BEAM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BEAM vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BEAM$1.89B+4.66%-14.07x2.21x
HRMY$1.89B+2.96%15.39x3.16x
MRVI$1.88B+0.67%-7.54x4.31x
MIRM$1.93B+5.04%-17.19x8.42x
ARVN$1.85B+1.78%-5.62x3.15x

Beam Therapeutics Stock FAQ

What is Beam Therapeutics's quote symbol?

(NASDAQ: BEAM) Beam Therapeutics trades on the NASDAQ under the ticker symbol BEAM. Beam Therapeutics stock quotes can also be displayed as NASDAQ: BEAM.

If you're new to stock investing, here's how to buy Beam Therapeutics stock.

What is the 52 week high and low for Beam Therapeutics (NASDAQ: BEAM)?

(NASDAQ: BEAM) Beam Therapeutics's 52-week high was $49.50, and its 52-week low was $18.85. It is currently -53.68% from its 52-week high and 21.64% from its 52-week low.

How much is Beam Therapeutics stock worth today?

(NASDAQ: BEAM) Beam Therapeutics currently has 82,415,619 outstanding shares. With Beam Therapeutics stock trading at $22.93 per share, the total value of Beam Therapeutics stock (market capitalization) is $1.89B.

Beam Therapeutics stock was originally listed at a price of $18.75 in Feb 6, 2020. If you had invested in Beam Therapeutics stock at $18.75, your return over the last 4 years would have been 22.29%, for an annualized return of 5.16% (not including any dividends or dividend reinvestments).

How much is Beam Therapeutics's stock price per share?

(NASDAQ: BEAM) Beam Therapeutics stock price per share is $22.93 today (as of Nov 1, 2024).

What is Beam Therapeutics's Market Cap?

(NASDAQ: BEAM) Beam Therapeutics's market cap is $1.89B, as of Nov 4, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Beam Therapeutics's market cap is calculated by multiplying BEAM's current stock price of $22.93 by BEAM's total outstanding shares of 82,415,619.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.